Skip to content

Startup & venture capital news

Star Therapeutics raises USD 200 million for rare disease medicines

OrbiMed and Janus Henderson Investors co lead the financing.

By /

LinkedInX
Star Therapeutics: Star Therapeutics raises USD 200 million for rare disease medicines
Fierce Biotech

Star Therapeutics announced USD 200 million in private financing on 23 October 2026, co led by OrbiMed and Janus Henderson Investors. The South San Francisco biotechnology company develops therapies through a portfolio of focused subsidiaries. Founder and chief executive Adam Rosenthal leads the group, whose programmes include treatments for bleeding disorders and other rare diseases. Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile Group, Sofinnova Investments and Soleus Capital also participated. The announcement does not identify a conventional Series stage, so the round remains classified as undisclosed.

Keep reading

More Funding

All stories